GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (NAS:ADPT) » Definitions » Price-to-Free-Cash-Flow
中文

Adaptive Biotechnologies (Adaptive Biotechnologies) Price-to-Free-Cash-Flow

: N/A (As of Today)
View and export this data going back to 2019. Start your Free Trial

As of today (2024-04-23), Adaptive Biotechnologies's share price is $2.57. Adaptive Biotechnologies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.16. Hence, Adaptive Biotechnologies's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Adaptive Biotechnologies's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 7 years, Adaptive Biotechnologies's highest Price-to-Free-Cash-Flow Ratio was 76.08. The lowest was 24.54. And the median was 53.30.

ADPT's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.29
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Adaptive Biotechnologies's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.20. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.16.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 3.40% per year.

During the past 7 years, Adaptive Biotechnologies's highest 3-Year average Free Cash Flow per Share Growth Rate was 3.40% per year. The lowest was -70.80% per year. And the median was -53.80% per year.


Adaptive Biotechnologies Price-to-Free-Cash-Flow Historical Data

The historical data trend for Adaptive Biotechnologies's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial 10.66 - - - -

Adaptive Biotechnologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Adaptive Biotechnologies's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptive Biotechnologies Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's Price-to-Free-Cash-Flow falls into.



Adaptive Biotechnologies Price-to-Free-Cash-Flow Calculation

Adaptive Biotechnologies's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.57/-1.159
=N/A

Adaptive Biotechnologies's Share Price of today is $2.57.
Adaptive Biotechnologies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.16.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Adaptive Biotechnologies  (NAS:ADPT) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Adaptive Biotechnologies Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptive Biotechnologies (Adaptive Biotechnologies) Business Description

Traded in Other Exchanges
Address
1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").
Executives
Kyle Piskel officer: Principal Accounting Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Nitin Sood officer: Chief Commercial Officer, MRD C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Tycho Peterson officer: Chief Financial Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
R Mark Adams officer: Chief Operating Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Stacy L Taylor officer: SVP and General Counsel C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102
Leslie Trigg director C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112
Kevin T Conroy director 5505 ENDEAVOR LANE, MADISON WI 53719
Robert Hershberg director 3005 FIRST AVENUE, SEATTLE WA 98121
Peter M Neupert director 13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Sharon Benzeno officer: Chief Commercial Ofc Imm Med C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Harlan S Robins officer: Chief Scientific Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Francis Lo officer: Chief People Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michael J Pellini director 222 DUTTON MILL RD, WILLISTOWN PA 19380
Chad M Robins director, officer: CEO and Chairman C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102

Adaptive Biotechnologies (Adaptive Biotechnologies) Headlines

From GuruFocus